The expression and clinical significance of C1orf106 in low-grade serous ovarian cancer

Abstract Background Low-grade serous ovarian cancer is a rare subtype of ovarian cancer and lack of large-scale systematic studies worldwide.This study is aimed to select the target gene and figure out the expression and clinical significance of it in low-grade serous ovarian cancer. Methods and Results The mRNA data was downloaded from the Gene Expression Omnibus (GEO), then the differentially expressed genes (DEGs) between cancer and normal tissue were screened out by R software. Under comprehensive consideration, C1orf106 was chosen as our target gene based on the significant |logFC|, known molecular function and research innovation. Immunohistochemistry and qRT-PCR both showed that C1orf106 was highly expressed in tumor tissue. Contacted with clinical information, high-expression of C1orf106 was associated with lower Body Mass Index (< 25kg/m 2 ) and no residual lesion. Kaplan-Meier analysis showed that high-expression of C1orf106 was associated with better overall survival, but may not be correlated with progression-free survival. COX regression model indicated that C1orf106 was one of the prognostic factor for low-grade serous ovarian cancer, but not independently. Conclusion C1orf106 was highly expressed in low-grade serous ovarian cancer. High expression of C1orf106 indicated a better overall survival. Therefore, C1orf106 may be one of the biomarkers with diagnostic and prognostic value in low-grade serous ovarian cancer, but the precise mechanism still needs further research.